AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PATRYS LTD

0.025

+0.00631.58%

Volume:444.89K

Turnover:9.47K

Market Cap:- -

PE:- -

High:0.025

Open:0.019

Low:0.019

Close:0.019

52wk High:0.025

52wk Low:0.019

Shares:- -

Float Shares:- -

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

PATRYS LTD

Exchange:

ASX

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.patrys.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates live cell nuclei and inhibits mechanisms of DNA repair in target cancer cells. The company also focuses on developing PAT-DX1 as a treatment for metastatic triple negative breast cancer and glioblastoma. In addition, it engages in developing PAT-SC1's target/antigen CD55PAT-SC1, an isoform of the membrane-bound CD55 for the treatment of gastric cancer. Patrys Limited was founded in 2006 and is based in South Melbourne, Australia.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PABDA.AU/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PABDA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PABDA.AU\",,,,,undefined,":{"symbol":"PABDA.AU","market":"AU","secType":"STK","nameCN":"PATRYS LTD","latestPrice":0.025,"timestamp":1760330190712,"preClose":0.019,"halted":0,"volume":444891,"delay":0,"nameEN":"PATRYS LTD","floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":0.006,"latestTime":"10-13 15:57:09 AEDT","open":0.019,"high":0.025,"low":0.019,"amount":9472,"amplitude":0.315789,"askPrice":0.029,"askSize":33333,"bidPrice":0.025,"bidSize":280002,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1760331600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.019,"openAndCloseTimeList":[[1760310000000,1760331600000]],"volumeRatio":0,"lotSize":0,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PABDA.AU\",,,,,undefined,":{"symbol":"PABDA.AU","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0.025,"amplitude":0.315789,"preClose":0.019,"low":0.019,"week52Low":0.019,"pbRate":"--","week52High":0.025,"institutionHeld":0,"latestPrice":0.025,"committee":0.787237,"eps":0,"divideRate":0,"volume":444891,"delay":0,"ttmEps":0,"open":0.019},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PABDA.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-10-22","symbol":"PABDA.AU","reason":null,"defaultRemindTime":1761087600000,"announcedDate":"2025-09-08","type":"delisting","dateTimestamp":1761051600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PABDA.AU\",market:\"AU\",,,undefined,":[],"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.patrys.com","compareEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0133},{"period":"3month","weight":0.0484},{"period":"6month","weight":0.1543},{"period":"1year","weight":0.2258},{"period":"ytd","weight":0.2061}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates live cell nuclei and inhibits mechanisms of DNA repair in target cancer cells. The company also focuses on developing PAT-DX1 as a treatment for metastatic triple negative breast cancer and glioblastoma. In addition, it engages in developing PAT-SC1's target/antigen CD55PAT-SC1, an isoform of the membrane-bound CD55 for the treatment of gastric cancer. Patrys Limited was founded in 2006 and is based in South Melbourne, Australia.","exchange":"ASX","name":"PATRYS LTD","nameEN":"PATRYS LTD"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PABDA.AU\",market:\"AU\",,,undefined,":null}}